公开(公告)号：WO2022241398A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/072205

申请日：2022-05-09

Applicant: MEDIMMUNE, LLC

Inventor： OGANESYAN, Vaheh, Yuni ,  SHAN, Lu

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/00 ,  C07K16/28

Abstract: The present disclosure relates to modified FcRn binding fragments with improved half-life, specifically fusion proteins and polypeptides comprising said modified FcRn binding fragments, and methods of manufacturing said fusion proteins and their use in methods of treatment.

公开(公告)号：WO2021113233A1

公开(公告)日：2021-06-10

申请号：PCT/US2020/062695

申请日：2020-12-01

Applicant: MEDIMMUNE, LLC

Inventor： FLOR, Armando ,  AMBERY, Philip

IPC: C07K14/435 ,  C07K14/605 ,  A61P3/04 ,  A61P3/10 ,  A61K38/00

Abstract: Provided herein are methods of improving glycemic control, reducing weight, and/or treating type 2 diabetes mellitus in human patients comprising administering GLP-1/glucagon agonist peptides, dapagliflozin, and metformin.

公开(公告)号：WO2021080608A1

公开(公告)日：2021-04-29

申请号：PCT/US2019/058120

申请日：2019-10-25

Applicant: MEDIMMUNE, LLC

Inventor： DIMASI, Nazzareno ,  KUMAR, Amit

IPC: A61K47/68 ,  C07D207/452 ,  C07K16/30 ,  A61P35/00

Abstract: A tri-functional linker moiety: formula (I), where X and Y are linking chains, and its use for preparing dual-mechanistic drug conjugates, preferably in a site-specific manner.

公开(公告)号：WO2021007101A8

公开(公告)日：2021-01-14

申请号：PCT/US2020/040675

申请日：2020-07-02

Applicant: MEDIMMUNE, LLC

Inventor： LIN, Jia ,  CHRISTIE, Ronald, James ,  GAO, Changshou

IPC: C07C13/08 ,  C07C13/15 ,  C07C47/44 ,  C07K1/1077

Abstract: The present invention provides conjugates of a first polypeptide and a second polypeptide wherein the link between the first polypeptide and the second polypeptide comprises the following moiety.

公开(公告)号：WO2020240502A2

公开(公告)日：2020-12-03

申请号：PCT/IB2020/055128

申请日：2020-05-29

Applicant: MEDIMMUNE, LLC ,  DANA-FARBER CANCER INSTITUTE, INC

Inventor： KINNEER, Krista ,  TICE, David Alan ,  COATS, Steven ,  TAI, Yu-Tzu ,  ANDERSON, Kenneth

IPC: A61K39/395 ,  A61K39/44 ,  C07K16/28 ,  A61P35/00 ,  A61P35/02 ,  A61K31/407 ,  A61K31/427 ,  A61K31/69 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  C07K16/2878 ,  C07K2317/73 ,  C07K2317/92

Abstract: The disclosure relates to methods and compositions for the treatment of a B-cell malignancy. Specifically, the disclosure relates to a B-cell malignancy medicament or composition, comprising: (a) an antibody-drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA), conjugated to a nucleic acid cross-linking agent; and (b) a proteasome inhibitor.

公开(公告)号：WO2020185986A1

公开(公告)日：2020-09-17

申请号：PCT/US2020/022226

申请日：2020-03-12

Applicant: MEDIMMUNE, LLC

Inventor： ESSER, Mark ,  RUZIN, Alexey ,  JAFRI, Hasan ,  SHOEMAKER, Kathryn ,  SELLMAN, Bret ,  YU, Li

IPC: C07K16/12 ,  C12Q1/689

Abstract: The present disclosure is directed to methods of treating subjects colonized with S aureus with an anti-alpha toxin antibody or antigen-binding fragment thereof. The methods can decrease the incidence of infection attendant to the presence of S. aureus in the subject.

公开(公告)号：WO2020081956A1

公开(公告)日：2020-04-23

申请号：PCT/US2019/056974

申请日：2019-10-18

Applicant: MEDIMMUNE, LLC

Inventor： YU, Li ,  YANG, Harry ,  DAR, Mohammed ,  ROSKOS, Lorin ,  SORIA, Jean-charles ,  FERTE, Charles ,  ZHAO, Wei ,  GENDRIN BROKMANN, Aline ,  FARIA, Jolyon ,  MUKHOPADHYAY, Pralay

IPC: C12Q1/6886 ,  G16H20/00 ,  G16H10/20

Abstract: Methods for determining treatments for cancer patients are disclosed, including measurement of multiple clinicopathological marker concentrations for gradient boosting machine learning analysis.

公开(公告)号：WO2020081783A3

公开(公告)日：2020-04-23

申请号：PCT/US2019/056691

申请日：2019-10-17

Applicant: MEDIMMUNE, LLC

Inventor： HAMMOND, Scott ,  CHIOU, Victoria ,  STREICHER, Katie ,  LE, Ngocdiep ,  TOWNSLEY, Danielle

IPC: A61K39/395 ,  C07K16/28

Abstract: This disclosure relates to a monoclonal antibody directed against 0X40 or an antigen-binding fragment thereof, and the use of such antibody or antigen-binding fragment thereof in the treatment of tumors. The disclosure also relates to methods for the treatment of tumors comprising administering to a patient in need thereof an anti-OX40 antibody or antigenbinding fragment thereof in combination with a monoclonal antibody directed against programmed death-ligand l(PD-Ll), also known as B7 homolog 1 (B7-H1) or an antigenbinding fragment thereof or in combination with a monoclonal antibody directed against Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or an antigen-binding fragment thereof.

公开(公告)号：WO2020076790A1

公开(公告)日：2020-04-16

申请号：PCT/US2019/055144

申请日：2019-10-08

Applicant: MEDIMMUNE, LLC ,  HUMABS BIOMED SA

Inventor： TKACZYK, Christine ,  SELLMAN, Bret ,  DU, Qun ,  DAMSCHRODER, Melissa ,  CORTI, Davide ,  MINOLA, Andrea

IPC: C07K16/12 ,  A61K39/085 ,  A61P31/00 ,  A61K39/00

Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.

公开(公告)号：WO2020051331A1

公开(公告)日：2020-03-12

申请号：PCT/US2019/049745

申请日：2019-09-05

Applicant: MEDIMMUNE, LLC

Inventor： BRITTON, Zachary ,  MERELLI, Marcello ,  BOWEN, Michael, A. ,  LONDON, Timothy ,  ZHUANG, Li ,  CHAKRABARTI, Lina

IPC: C12P21/02 ,  C07K14/435 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/40 ,  C07K16/46 ,  C07K17/08 ,  A61K47/50 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/60 ,  C12Y601/01026

Abstract: The present invention is directed to methods of screening populations of transgenic cells for cells that produce a protein of interest. The methods comprise culturing transgenic cells in culture conditions that include at least one non-natural amino acid (nnAA) in the cell culture medium. The transgenic cells comprise at least one polynucleotide that codes for a fusion protein with a first domain coding for a protein of interest and a second domain coding for a domain that facilitates detection of the transgenic cells that express the protein of interest when the transgenic cell expresses the second domain.